HR 796
Second Chance for Moms Act
Summary
Second Chance for Moms Act of 2025 This bill requires labeling of the drug mifepristone to include certain information about the hormone progesterone and establishes a related telephone hotline. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.)
Bill status
- Status
- In committee
- Sponsor
- Rep. Mary E. Miller [R-IL-15]
- Cosponsors
- 13
- Policy area
- Health
- Introduced
- 2025-01-28
- Latest action
- 2025-01-28: Referred to the House Committee on Energy and Commerce.
Committee referrals
Recent actions
- 2025-01-28: Referred to the House Committee on Energy and Commerce.
- 2025-01-28: Introduced in House
- 2025-01-28: Introduced in House